Research programme: biosimilars - Momenta Pharmaceuticals

Drug Profile

Research programme: biosimilars - Momenta Pharmaceuticals

Alternative Names: Aflibercept biosimilar - Momenta Pharmaceuticals; M 710; M-511; MYL-1701P

Latest Information Update: 21 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Momenta Pharmaceuticals
  • Developer Momenta Pharmaceuticals; Mylan
  • Class Anti-inflammatories; Antineoplastics; Eye disorder therapies; Monoclonal antibodies; Proteins
  • Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Diabetic macular oedema; Inflammation
  • Research Cancer

Most Recent Events

  • 31 Jan 2018 US FDA accepts the IND application for aflibercept biosimilar in Diabetic macular oedema
  • 03 Jan 2018 Momenta Pharmaceuticals and Mylan plan a pivotal phase III trial of aflibercept biosimilar in Diabetic macular oedema (Intravitreous) in August 2018 (NCT03610646)
  • 03 Jan 2018 Preclinical trials in Diabetic macular oedema in USA (Parenteral) before January 2018 (Momenta Pharmaceuticals Pipeline,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top